PFS and OS in M13-982 patients with R/R CLL and in MURANO patients with R/R CLL and del(17p)/TP53 mutation. (A) PFS from treatment initiation in 153 patients from M13-982. (B) PFS from randomization in 53 patients from MURANO. (C) OS in 153 patients from M13-982. (D) OS in 53 patients from MURANO. mut, mutated; NA, not applicable.